Regeneron reported Eylea sales of $4.7 billion in the first six months of the year - a decline of 4%, with $2.9 billion from that total coming from the US market. Sales of Vabysmo, meanwhile ...

Analysts are intrested in these 5 stocks: ( ($MRK) ), ( ($REGN) ), ( ($CLRB) ), ( ($HUMA) ) and ( ($FL) ). Here is a ...

The MERLIN study was comparing Beovu to Eylea ... drug's sales momentum if approved. Filings are due before the end of the year. Bayer's CEO says new product launches will offset the decline ...

Regeneron anticipates a decline in EYLEA sales due to biosimilar competition. DUPIXENT continues to expand globally, with significant growth expected by 2030. The company is investing $7 billion in ...

Me gene privacy question takes a turn in bankruptcy Why a big AI player wants a quarter-million bucks from 23andMe Why a big ...

Since recreational cannabis was legalized in Illinois starting in 2020, sales of the drug have increased to $2 billion a year. The holiday this year has morphed into a weekendlong cultural ...

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

The latest price target for Regeneron Pharmaceuticals (NASDAQ:REGN) was reported by Citigroup on May 14, 2025. The analyst firm set a price target for $700.00 expecting REGN to rise to within 12 ...

Explore Regeneron Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for REGN. Sanofi plans $20 billion US investment by 2030 to expand R&D and ...